Laura M.
- Country
- France
- Department
- Clinical research department
Research Overview
- Evaluation of AZD2014 and Anastrozole in Metastatic Hormone Receptor-Positive Endometrial Adenocarcinoma: A Phase I/II Multicentric, Randomized, Open-Label Study
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Palazestrant and Ribociclib versus Letrozole and Ribociclib for First-line Treatment of ER+/HER2- Advanced Breast Cancer
Data & Insights
Has run more than one trial at 416 of 710 partner sites.
Specializations
Breast Cancer Research
Specializes in treating various forms of breast cancer, with particular emphasis on hormone receptor-positive (HR+) and HER2-negative variants. Focuses on advanced and metastatic disease management.
- Triple Negative Breast Cancer (TNBC)
- Early-stage HER2-positive breast cancer
- Advanced hormone receptor-positive disease
Investigates novel combination therapies including immunotherapy approaches and targeted treatments for breast cancer subtypes.
Gynecologic Oncology
Conducts research in various gynecologic malignancies, with expertise in ovarian cancer and endometrial cancer treatment approaches.
- High-grade serous ovarian cancer
- Low-grade serous ovarian cancer
- Advanced endometrial carcinoma
Explores innovative therapeutic strategies including maintenance treatments and biomarker-driven approaches.
Precision Medicine
Focuses on developing biomarker-driven treatments and personalized therapeutic approaches for gynecologic and breast malignancies.
- Molecular profiling studies
- Targeted therapy development
- Immunotherapy applications
Implements novel clinical trial designs to evaluate efficacy of personalized treatment strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.